Abstract:In high-income countries, population screening for glaucoma is not considered to be a cost-effective intervention.1Moyer VA Screening for glaucoma: US Preventive Services Task Force Recommendation Statement.Ann Intern Med. 2013; 159: 484-489PubMed Google Scholar, 2Royal College of OphthalmologistsCommissioning guide: glaucoma. Royal College of Ophthalmologists, London2016Google Scholar, 3Prum Jr., BE Rosenberg LF Gedde SJ et al.Primary open-angle glaucoma preferred practice pattern guidelines.Ophthalmology. 2016; 123: 41-111Summary Full Text Full Text PDF PubMed Scopus (368) Google Scholar However, in The Lancet Global Health, Jianjun Tang and colleagues show in their economic evaluation of population-based screening for both primary angle-closure glaucoma (PACG) and primary open-angle glaucoma (POAG) that such a strategy is likely to be cost-effective in China.4Tang J Liang Y O'Neill C Kee F Jiang J Congdon N Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model.Lancet Glob Health. 2019; (published online May 20.)http://dx.doi.org/10.1016/S2214-109X(19)30201-3Summary Full Text Full Text PDF PubMed Scopus (37) Google Scholar The authors further report that in urban China, the combined PACG and POAG screening would dominate over the no intervention scenario—that is, money saved from having to provide less glaucoma treatment exceeds the actual investment cost of glaucoma screening. In rural China, the incremental cost-effectiveness ratio is US$1280 (95% CI −58 to 7940) for each quality-adjusted life-year gained and remains well below the estimated per-capita GDP in rural China ($4010). The authors credit these results to the relatively high glaucoma incidence and low cost of screening in China. The analysis, however, represents an optimistic evaluation of the cost-effectiveness of population-based screening of glaucoma in China, and whether its feasibility as a national intervention in other settings where the cost structure—particularly the cost of human resources—is substantially different remains a matter of further investigation. Population screening of glaucoma needs to be a state-sponsored programme. It is unlikely that local communities would spontaneously participate and achieve a high screening coverage without the stimulation and support from governmental health institutes. On the other hand, active community screening projects such as the Wenzhou Glaucoma Screening Program5Liang Y Jiang J Ou W et al.Effect of community screening on the demographic makeup and clinical severity of glaucoma patients receiving care in urban China.Am J Ophthalmol. 2018; 195: 1-7Summary Full Text Full Text PDF PubMed Scopus (17) Google Scholar require substantial organisational and logistical efforts and might not be replicable across the country. In the current Chinese context, a feasible and sustainable way to fund an ongoing population screening programme for glaucoma could be through its national health insurance system. Despite its split operation in rural and urban China and its large geographical variations, the national health insurance system has managed to cover more than 95% of the Chinese population.6Yu H Universal health insurance coverage for 1·3 billion people: what accounts for China's success?.Health Policy. 2015; 119: 1145-1152Crossref PubMed Scopus (196) Google Scholar Including glaucoma screening as a part of the routine annual check-up and allowing it to be reimbursable through the health insurance scheme will certainly improve the accessibility and sustainability of the programme. Although the screening cost for glaucoma is notably low in Tang and colleagues' estimation ($2·52 for PACG and $3·20 for POAG per screening),4Tang J Liang Y O'Neill C Kee F Jiang J Congdon N Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model.Lancet Glob Health. 2019; (published online May 20.)http://dx.doi.org/10.1016/S2214-109X(19)30201-3Summary Full Text Full Text PDF PubMed Scopus (37) Google Scholar provision of screening to 400 million people older than 50 years of age remains a logistical and financial challenge. A further budget impact analysis of the intervention would help to clarify its implications to the national health budget. The implementation of a nationwide glaucoma screening programme requires the country to address the substantial inequality in health-care accessibility across urban and rural China.7Zhang T Xu Y Ren J Sun L Liu C Inequality in the distribution of health resources and health services in China: hospitals versus primary care institutions.Int J Equity Health. 2017; 16: 42Crossref PubMed Scopus (150) Google Scholar As Tang and colleagues' report, the provision of screening in urban China is far more cost-effective than that in rural areas.4Tang J Liang Y O'Neill C Kee F Jiang J Congdon N Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov model.Lancet Glob Health. 2019; (published online May 20.)http://dx.doi.org/10.1016/S2214-109X(19)30201-3Summary Full Text Full Text PDF PubMed Scopus (37) Google Scholar This result probably only reflects better accessibility due to the greater availability of health-care infrastructure and networks in urban China. Inequality in accessing health care is substantial between urban and rural China, with most health resources concentrated in urban areas.8Gong P Liang S Carlton EJ et al.Urbanisation and health in China.Lancet. 2012; 379: 843-852Summary Full Text Full Text PDF PubMed Scopus (824) Google Scholar As a result, rural residents are often required to seek health care in urban areas, which inevitably increases the demand for care in urban China. To cope with the demand, further health resources are poured into urban areas, leading to a vicious cycle that continues to widen the inequality gap. Further economic evaluation should aim to identify the most economical solution to reduce the disease burden of glaucoma and at the same time limit the widening of inequality in accessing eye care. In high-income countries with predominantly white populations, PACG prevalence is very low and population screening often focuses on POAG alone. By contrast with the existing body of evidence that does not support population screening for POAG in such countries, this study's evaluation of combined screening for both POAG and PACG shows good population impact and cost-effectiveness in a developing country setting. This research highlights the importance of taking into consideration the socioeconomic and demographic differences while implementing national programmes in various economic settings and emphasises that the solution is often not universal. Tang and colleagues have identified an important knowledge bias in the understanding of health economics of glaucoma intervention. If proven feasible, the study's recommendations could substantially change the current clinical practices for glaucoma screening in China, and perhaps in other resource-limited settings, and achieve a large gain in its population health. Conclusively, the key take-home message from this Tang and colleagues' Article is simple. High disease incidence, low screening cost, and the advantage of combined POAG and PACG screening are all key determining factors of cost-effectiveness of a population glaucoma screening programme. The implementation of such a programme in reality requires strong leadership and sponsorship from the state. We declare no competing interests. Cost-effectiveness and cost-utility of population-based glaucoma screening in China: a decision-analytic Markov modelPopulation screening for glaucoma (POAG and PACG combined) is likely to be cost-effective in both urban and rural China. Future studies should investigate the effectiveness of interventions to improve acceptance of definitive care among people screened. Full-Text PDF Open Access

Daily cost of glaucoma medications in China.

[Changes in the types and daily treatment costs of anti-glaucoma eye drops in China in recent 15 years].

Changes of the Types and Daily Costs of Topical Antiglaucoma Medications from 2006 to 2021 in China

Fixed-combination Treatments for Intraocular Hypertension in Chinese Patients – Focus on Bimatoprost-Timolol

Cost-utility analysis of commonly used anti-glaucoma interventions for mild-to-moderate primary open-angle glaucoma patients in rural and urban China

Cost-Utility Analysis of Minimally Invasive Glaucoma Surgeries for Patients with Mild-to-Moderate Primary Open-Angle Glaucoma in Rural and Urban China

Comparison of Latanoprost and Brimonidine in the Treatment of Open Angle Glaucoma

Cost-effectiveness analysis of tafluprost versus latanoprost in the treatment of primary open-angle glaucoma

Intraocular Pressure-Lowering Efficacy and Safety of Bimatoprost 0.03% Therapy for Primary Open-Angle Glaucoma and Ocular Hypertension Patients in China.

Safety and Efficacy of Bimatoprost/timolol Fixed Combination in Chinese Patients with Open-Angle Glaucoma or Ocular Hypertension.

Intraocular pressure-reducing effects of latanoprost versus timolol in chinese patients with chronic angle-closure glaucoma.

A Population-Based Assessment of 24-Hour Intraocular Pressure among Subjects with Primary Open-Angle Glaucoma: the Handan Eye Study

Meta-analysis of randomized controlled trials comparing latanoprost with timolol in the treatment of Asian populations with chronic angle-closure glaucoma.

Clinical Outcome and Medical Cost of Originator and Generic Antihypertensive Drugs: A Population-Based Study in Yinzhou, China

Survey and analysis of accessibility, availability, and affordability of topical glaucoma medicines

Is Population-Based Glaucoma Screening Cost-Effective in China?

Clinical Investigation:The Intraocular Pressure-lowering Efficacy and Safety of Brinzolamide Combined with Betaxolol

Comparison of Intraocular Pressure Reducing Effects of Three Prostaglandin Eyedrops in Open-Angle Glaucoma

Pharmaco-economic Analysis of Applying Prostaglandins Analogue for the Treatment of ;Glaucoma

Efficacy and Safety of Prostaglandin Analogues in Primary Open-Angle Glaucoma or Ocular Hypertension Patients

A 12-Week, Double-Masked, Parallel-Group Study of the Safety and Efficacy of Travoprost 0.004% Compared with Pilocarpine 1% in Chinese Patients with Primary Angle-Closure and Primary Angle-Closure Glaucoma